Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
L-Ornithine L-Aspartate (LOLA) is a combination of two amino acids, ornithine and aspartate. It is thought to stimulate the detoxification of ammonia in the liver and peripheral tissues and to improve energy metabolism.
## Primary Indications
* Supportive treatment of latent and manifest hepatic encephalopathy (HE) in patients with chronic liver disease.
## Adult Dosing
* **Oral:** Typically 3000 mg to 6000 mg (3 to 6 grams) three times daily.
* **Intravenous:** Typically 5 grams to 10 grams daily, administered as a slow infusion. The exact dosage and frequency may depend on the severity of hepatic encephalopathy and local protocol.
## Pediatric Dosing
* There is limited well-established pediatric dosing for L-Ornithine L-Aspartate. Dosing in pediatric patients should be based on clinical judgment and consultation with literature or specialized resources, and is often extrapolated from adult data or weight-based calculations.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment, but caution should be exercised.
## Contraindications
* Severe renal impairment.
* Known hypersensitivity to ornithine, aspartate, or any component of the formulation.
* Rarely, patients with AV block may require caution due to potential electrolyte effects.
## Adverse Effects
* Gastrointestinal disturbances: nausea, vomiting, abdominal pain, diarrhea.
* Rarely: skin rash, headache, dizziness.
* With IV administration: local irritation at the injection site.
## Key Drug Interactions
* No significant drug interactions have been definitively established. However, monitor patients receiving other medications that affect ammonia levels or liver function.
## Monitoring
* Monitor for signs and symptoms of hepatic encephalopathy.
* Monitor electrolytes, especially in patients with renal impairment or at risk.
* Monitor liver function tests periodically.
## Clinical Pearls
* LOLA is often used as an adjunct to other therapies for hepatic encephalopathy.
* The oral formulation may be used for long-term management of latent HE, while IV formulations are typically used for more acute or severe presentations.
* It is crucial to ensure adequate hydration, especially with IV administration.
***
***Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant literature for complete details regarding indications, contraindications, warnings, precautions, adverse reactions, drug interactions, and dosing before use. Practice guidelines and local protocols may influence therapeutic decisions.*
